Abstract:Abstract Background Reduced serum levels of high density lipoprotein cholesterol (HDL-C) is a hallmark of the metabolic syndrome. Epidemiologic studies have reported an inverse correlation between HDL- C and cardiovascular disease (CVD) risk. However, recent works suggest that the association is strongest in healthy individuals. Changes in particle number and functional properties of HDL may more closely reflect CVD prognosis in patients with pre-existent disease. The majority of such patients receive statin treatment, which affects both HDL-C levels, and particle composition. Hence, serum apoA1 and the HDL-C:apoA1 ratio have been proposed as more sensitive indicators of cardio-metabolic prognosis. Purpose We studied the associations of serum HDL-C, apoA1 and the HDL-C: apoA1 ratio to long term risk of CVD mortality and incident type 2 diabetes (T2D) patients with suspected stable angina pectoris (SAP). Methods A total of 41064 patients underwent elective coronary angiography in 2000–2004 and were followed-up for CVD mortality throughout 2016. In a subgroup of 2519 participants without verified or possible diabetes at baseline, the associations to incident type 2 diabetes (T2D) were evaluated throughout 2014. Information on clinical endpoints was obtained through national health registries. Risk estimates are reported per 1 SD increment of (log transformed) biomarkers and were calculated by cox or logistic regression. We explored risk classification by calculating the continuous net reclassification improvement (NRI). Results At inclusion, median (25th-75th percentiles) age was 62 (55–70) years, 28% were women 76% had obstructive coronary artery disease and 80% received statins. During median (25th-75th percentiles) 13.9 (12.0–15.3) years of follow-up, 14.1% of the participants died from CVD. After multivariate adjustment (age, gender, body mass index, HbA1c, triglycerides, statin treatment, fasting status) HDL and apoA1, but not the HDL: apoA1 ratio, significantly predicted CVD mortality. The hazard ratio (HR) and 95% confidence interval (CI) was: 0.86 (0.78–0.94), 0.88 (0.80–0.98) and 0.96 (0.86–1.03) for HDL-C, apoA1 and the HDL-C:apoA1 ratio, respectively. HDL-C was the only of the evaluated biomarkers providing a significant NRI (95% CI) of 0.14 (0.04–0.19). In the subset evaluated for incdent T2D, HDL-C provided multivariate adjusted odds ratios (OR; 95% CI) and NRI (95% CI) of 0.69 (0.58–0.82) and 0.34 (0.21–0.47) for new onset TSD. The corresponding OR (95% CI) and NRI (95% CI) for apoA1 were: 0.85 (0.73–0.99) and 0.20 (0.06–0.33), respectively. The HDL:apo A1 ratio provided an OR (95% CI) of 0.66 (0.55–0.80) and NRI (95% CI) of 0.24 (0.11–0.37) for T2D. No significant effect modifications according to statin treatment were found (P≥0.22). Conclusion Among patients with suspected SAP, of which the majority received statins, HDL-C was non-inferior to apoA1 and the HDL:apoA1 ratio in predicting long term risk of CVD mortality and T2D. Funding Acknowledgement Type of funding source: Public hospital(s). Main funding source(s): Department of Heart Disease, Haukeland University Hospital; Department of Clinical Science, University of Bergen

Low Apolipoprotein A1 was associated with increased risk of cancer mortality in patients following percutaneous coronary intervention: A 10‐year follow‐up study

Serum Apolipoprotein-A2 Levels Are a Strong Predictor of Future Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention

Prognostic Significance of Pretreatment Apolipoprotein A-I as a Noninvasive Biomarker in Cancer Survivors: A Meta-Analysis

Associations of HDL-C and ApoA-I with Mortality Risk in PCI Patients Across Different hsCRP Levels

Apolipoprotein A-I levels in the survival of patients with colorectal cancer: a retrospective study

Apolipoprotein A1: a Novel Serum Biomarker for Predicting the Prognosis of Hepatocellular Carcinoma after Curative Resection

Apolipoprotein A1 Is Associated with Pulmonary Vascular Resistance and Adverse Clinical Outcomes in Patients with Pulmonary hypertension secondary to Heart Failure

The Value of the Apolipoprotein B/Apolipoprotein A1 Ratio in Predicting the Rapid Progression of Non-Culprit Coronary Lesions in Acute Coronary Syndrome in Patients with Diabetes Mellitus after Percutaneous Coronary Intervention

Coronary Artery Disease: Optimal Lipoprotein(a) for Survival—Lower Is Better? A Large Cohort With 43,647 Patients

Association of Apolipoprotein A1, High Density Lipoprotein Cholesterol, and Their Ratio with Inflammatory Marker in Chinese Adults with Coronary Artery Disease

HDL, apo a1 and long-term cardio-metabolic prognosis in statin-treated patients with suspected stable angina pectoris: a prospective cohort study

Serum apolipoproteins and mortality risk: evidence from observational and Mendelian randomization analyses

Elevated Apolipoprotein B Predicts Poor Postsurgery Prognosis in Patients with Hepatocellular Carcinoma.

Association of systemic inflammation with the serum apolipoprotein A-1 level: A cross-sectional pilot study

Baseline White Blood Cell Count-to-apolipoprotein A1 Ratio As a Novel Predictor of Long-Term Adverse Outcomes in Patients Who Underwent Percutaneous Coronary Intervention: a Retrospective Cohort Study

Serum amyloid A-low-density-lipoprotein complex and cause-specific mortality in patients with suspected or known coronary artery disease: The ANOX Study

Elevated ApoB/apoA-1 is Associated with in-Hospital Mortality in Elderly Patients with Acute Myocardial Infarction

A V-shaped association between high-density lipoprotein cholesterol levels and poor outcomes in patients after percutaneous coronary intervention

Predictive Value of Apolipoprotein for Coronary Atherosclerosis in Asymptomatic Non-Diabetic Population.

Usefulness of Lipoprotein (a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction

Influence of Serum Apelin and CD40L Expression Levels on Adverse Cardiovascular Events after PCI